{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:37:15Z","timestamp":1790109435707,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lansea.2025.100680","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:54:27Z","timestamp":1761652467000},"page":"100680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characteristics of long term survivors of multiple myeloma after autologous stem cell transplantation: a retrospective analysis from a tertiary care centre in India"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-2500","authenticated-orcid":false,"given":"Lalit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajegowda","family":"Chethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Singh Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahitagni","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omdutt","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya Ranjan","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lansea.2025.100680_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"PERSEUS trial investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lansea.2025.100680_bib2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lansea.2025.100680_bib3","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10192","key":"10.1016\/j.lansea.2025.100680_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lansea.2025.100680_bib5","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lansea.2025.100680_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG research project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.lansea.2025.100680_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cam4.1283","article-title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.lansea.2025.100680_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-024-01062-2","article-title":"Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lansea.2025.100680_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.936993","article-title":"Long-term responders after autologous stem cell transplantation in multiple myeloma","volume":"12","author":"Oliver-Caldes","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.lansea.2025.100680_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.lansea.2025.100680_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-020-00353-8","article-title":"Character- istics of exceptional responders to autologous stem cell transplantation in mul- tiple myeloma","volume":"10","author":"Paquin","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lansea.2025.100680_bib12","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00277-020-04060-z","article-title":"Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.lansea.2025.100680_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/10428194.2022.2148214","article-title":"Autologous stem cell transplant for multiple myeloma: impact of melphalan dose on the transplant outcome","volume":"64","author":"Kumar","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.lansea.2025.100680_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2021.07.030","article-title":"Multiple myeloma: risk adapted use of Plerixafor for stem cell mobilization prior to autologous stem cell transplantation is effective and cost efficient","volume":"22","author":"Prakash","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.lansea.2025.100680_bib15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.lansea.2025.100680_bib16","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.lansea.2025.100680_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.lansea.2025.100680_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.102989","article-title":"India Obesity Commission Members. Revised definition of obesity in Asian Indians living in India","volume":"19","author":"Misra","year":"2025","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"10.1016\/j.lansea.2025.100680_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.lansea.2025.100680_bib20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/ijmr.IJMR_1593_18","article-title":"For AIIMS Myeloma Group. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome","volume":"149","author":"Kumar","year":"2019","journal-title":"Indian J Med Res"},{"issue":"20","key":"10.1016\/j.lansea.2025.100680_bib21","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lansea.2025.100680_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.lansea.2025.100680_bib23","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, Bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lansea.2025.100680_bib24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lansea.2025.100680_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2019.1663424","article-title":"Management of induction failures in newly diagnosed transplant-eligible multiple myeloma","volume":"61","author":"Gertz","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"34","key":"10.1016\/j.lansea.2025.100680_bib26","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","article-title":"Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials","volume":"27","author":"Harousseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lansea.2025.100680_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lansea.2025.100680_bib28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cam4.257","article-title":"Complete response after autologous stem cell transplant in multiple myeloma","volume":"3","author":"Kumar","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.lansea.2025.100680_bib29","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lansea.2025.100680_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajh.26439","article-title":"Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome","volume":"97","author":"Kaddoura","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lansea.2025.100680_bib31","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.4103\/jcrt.jcrt_503_22","article-title":"Autologous stem cell transplantation for multiple myeloma in the novel agent era: systematic review of Indian data and implications for resource constrained settings","volume":"19","author":"Singh","year":"2023","journal-title":"J Can Res Ther"},{"issue":"6","key":"10.1016\/j.lansea.2025.100680_bib32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.mjafi.2023.09.005","article-title":"Bone marrow transplant: a two-decade single centre hematology experience","volume":"79","author":"Kumar","year":"2023","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.lansea.2025.100680_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma","author":"Lindgren","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.lansea.2025.100680_bib34","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.lansea.2025.100680_bib35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41409-023-02017-0","article-title":"Dual assessment with multiparameter flow cytometry and 18F-FDG PET\/CT scan provides enhanced prediction of measurable residual disease after autologous haemopoietic stem cell transplant in myeloma-a prospective study","volume":"58","author":"Mookerjee","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.lansea.2025.100680_bib36","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1200\/JCO.23.00934","article-title":"Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival","volume":"42","author":"Pasquini","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.lansea.2025.100680_bib37","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood.2024027686","article-title":"Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma","volume":"145","author":"Terpos","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lansea.2025.100680_bib38","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00277-024-05865-y","article-title":"Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021","volume":"103","author":"Kysenius","year":"2024","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.lansea.2025.100680_bib39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13597","article-title":"Comorbidities in multiple myeloma and implications on survival: a population-based study","volume":"106","author":"Sverrisd\u00f3ttir","year":"2021","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.lansea.2025.100680_bib40","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.lansea.2025.100680_bib41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2016.158345","article-title":"Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma","volume":"102","author":"Gonz\u00e1lez-Calle","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lansea.2025.100680_bib42","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.lansea.2025.100680_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lansea.2025.100680_bib44","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/bmt.2017.29","article-title":"Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication","volume":"52","author":"Arteche-Lopez","year":"2017","journal-title":"Bone Marrow Transpl"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:35:32Z","timestamp":1764884132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368225001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"alternative-id":["S2772368225001519"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100680","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of long term survivors of multiple myeloma after autologous stem cell transplantation: a retrospective analysis from a tertiary care centre in India","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100680"}}